Diabetes Research and Clinical Practice 1997: Vol 38 Index

9 Pages·1997·2.1 MB·English

DIABETES RESEARCH
AND
CLINICAL PRACTICE
Diabetes Research and Clinical Practice 38 (1997) 207—209
Author index
Volume 38 (1997)
Acarbose Research Group, D., see Costa, B. 38, 33 Costa, B., C. Pifiol, D. and Acarbose Research Group, Acar-
Aerts, L., L. Vercruysse, F.A. Van Assche, The endocrine bose in ambulatory treatment of non-insulin-dependent dia-
pancreas in virgin and pregnant offspring of diabetic preg- betes mellitus associated to imminent sulfonylurea failure: A
nant rats 38, 9 randomised-multicentric trial in primary health-care 38, 33
Afshin-Nia, F., see Amini, M. 38, 185
Aguilar, J., see de Pablos-Velasco, P.L. 38, 191 Deepa, R., see Mohan, V. 38, 101
Amini, M., F. Afshin-Nia, N. Bashardoost, A. Aminorroaya, del Pozo, C., see Balsells, M. 38, 123
M. Shahparian, M. Kazemi, Prevalence and risk factors of de Pablos-Velasco, P.L., F.J. Martinez-Martin, J. Aguilar,
diabetes mellitus in the Isfahan city population (aged 40 or Prevalence of hypertension in IDDM patients in the North-
over) in 1993 38, 185 ern Grand Canary Island, according to the WHO/ISH and
Aminorroaya, A., see Amini, M. 38, 185
JNC-V/ADA criteria 38, 191
Anglada, J., see Balsells, M. 38, 123
Diamante, E., Renal involvement in type | (IDDM) diabetes
Arai, K., see Kanazawa, M. 38, 161
in Spain 38, 129
Asahi, Y., see Toide, K. 38, 151
Di Mauro, M., see Lunetta, M. 38, 81
Aso, Y., see Inukai, T. 38, 53
Drakoulakos, D., see Markopoulos, A.K. 38, 169
Dunbar, J.C., see Baydoun, R. 38, 1
Balsells, M., J. Viadé, M. Millan, J.R. Garcia, L. Garcia-Pas-
cual, C. del Pozo, J. Anglada, Prevalence of osteomyelitis in
Eastmond, R., see Foot, E.A. 38, 41
non-healing diabetic foot ulcers: usefulness of radiologic and
Elisabetta, Z., see Franzetti, I. 38, 173
scintigraphic findings 38, 123
Emanuela, M., see Franzetti, I. 38, 173
Bashardoost, N., see Amini, M. 38, 185
Esteva de Antonio, I., see Pareja, A. 38, 143
Baydoun, R., J.C. Dunbar, Impaired insulin but normal pen-
tagastrin effect on gastric acid secretion in diabetic rats: a
Fabregat, M.E., R. Gasa, C. Rodriguez, A. Novials, T. Gal-
role for nitric oxide 38, |
lart, W.J. Malaisse, R. Gomis, Autoantibodies against mito-
Belazi, M.A., see Markopoulos, A.K. 38, 169
chondrial glycerophosphate dehydrogenase in patients with
Bhatia, E., see Mohan, V. 38, 101
IDDM _ 38, 115
Bitar, M.S., C.W.T. Pilcher, I. Khan, R.J. Waldbillig, Dia-
Foot, E.A., R. Eastmond, Good metabolic and safety profile
betes-induced suppression of IGF-1 and its receptor mRNA
of troglitazone alone and following alcohol in NIDDM
levels in rat superior cervical ganglia 38, 73
subjects 38, 41
Boulton, A.J.M., see Shaw, J.E. 38, 21
Franzetti, I., D. Paolo, G. Marco, M. Emanuela, Z. Elisa-
Bowen, K., see Lowe, J.M. 38, 91
betta, U. Renato, Possible synergistic effect of metformin
Chen, H.-D., C.-K. Shaw, W.-P. Tseng, H.-I. Chen, M.-L. and enalapril on the development of hyperkaliemic lactic
Lee, Prevalence of diabetes mellitus and impaired glucose acidosis 38, 173
tolerance in Aborigines and Chinese in eastern Taiwan 38, Fujiwara, Y., see Inukai, T. 38, 53
199
Chen, H.-I., see Chen, H.-D. 38, 199 Gallart, T., see Fabregat, M.E. 38, 115
Chou, P., C.-L. Li, H.-S. Kuo, K.-J. Hsiao, Shih-Tzer Tsai, Garcia-Arnes, J., see Pareja, A. 38, 143
Comparison of the prevalence in two diabetes surveys in Garcia, J.R., see Balsells, M. 38, 123
Pu-Li, Taiwan, 1987-1988 and 1991-1992 38, 61 Garcia-Pascual, L., see Balsells, M. 38, 123
0168-8227/97/$17.00 © 1997 Elsevier Science Ireland Ltd. All rights reserved.
PIT S0168-8227(97)00117-4
208 Author index
Gasa, R., see Fabregat, M.E. 38, 115 Nakagami, T., see Miura, J. 38, 139
Gomis, R., see Fabregat, M.E. 38, 115 Nakayama, N., see Toide, K. 38, 151
Nicoletti, F., see Lunetta, M. 38, 81
Hayashi, T., see Kanazawa, M. 38, 161 Noma, Y., see Toide, K. 38, 151
Hsiao, K.-J., see Chou, P. 38, 61 Nomoto, S., see Kanazawa, M. 38, 161
Hukuda, G., see Kanazawa, M. 38, 161 Notoya, Y., see Kanazawa, M. 38, 161
Novials, A., see Fabregat, M.E. 38, 115
Ikeda, Y., see Miura, J. 38, 139
Inukai, T., Y. Fujiwara, K. Tayama, Y. Aso, Y. Takemura, Oka, Y., see Toide, K. 38, 151
Alterations in serum levels of 1%,25(OH), D, and osteocal- OkSa, A., see Skrha, J. 38, 25
cin in patients with early diabetic nephropathy 38, 53 Olveira, G., see Pareja, A. 38, 143
Omori, Y., see Miura,J . 38, 139
Iwamoto, Y., see Miura, J. 38, 139
Iwasaki, N., see Miura, J. 38, 139
Paolo, D., see Franzetti, I. 38, 173
Kanazawa, M., A. Tanaka, S. Nomoto, S. Shirabe, G. Pareja, A., F.J. Tinahones, F.J. Soriguer, A. Monzon, I.
Hukuda, K. Arai, Y. Notoya, T. Hayashi, K. Komeda, Y. Esteva de Antonio, J. Garcia-Arnes, G. Olveira, M.S. Ruiz
Kanazawa, Alterations of insulin and glucagon secretion de Adana, Unsaturated fatty acids alter the insulin secretion
from the perfused pancreas before, at the onset and after the response of the islets of Langerhans in vitro 38, 143
development of diabetes in male Otsuka Long-Evans PeruSitova, J., see Skrha, J. 38, 25
Tokushima Fatty (OLETF) rats 38, 161 Pilcher, C.W.T., see Bitar, M.S. 38, 73
Kanazawa, Y., see Kanazawa, M. 38, 161 Pifiol, C., see Costa, B. 38, 33
Kazemi, M., see Amini, M. 38, 185 Pont’uch, P., see Skrha, J. 38, 25
Khan, I., see Bitar, M.S. 38, 73 Poongothai, S., see Mohan, V. 38, 101
Kinalska, I., see Poplawska, A. 38, 109 Poplawska, A., M. Szelachowska, J. Topolska, B. Wysocka-
Komeda, K., see Kanazawa, M. 38, 161 Solowie, I. Kinalska, Effect of glycosaminoglycans on uri-
Kuo, H.-S., see Chou, P. 38, 61 nary albumin excretion in insulin-dependent diabetic
patients with micro- or macroalbuminuria 38, 109
Lavery, L.A., see van Houtum, W.H. 38, 177 Premalatha, G., see Mohan, V. 38, 101
Lee, M.-L., see Chen, H.-D. 38, 199
Le Moli, R., see Lunetta, M. 38, 81 Rema, M., see Mohan, V. 38, 101
Li, C.-L., see Chou, P. 38, 61 Renato, U., see Franzetti, I. 38, 173
Lowe, J.M., K. Bowen, Evaluation of a diabetes education Rodriguez, C., see Fabregat, M.E. 38, 115
program in Newcastle, NSW 38, 91 Ruiz de Adana, M.S., see Pareja, A. 38, 143
Lunetta, M., M. Di Mauro, R. Le Moli, F. Nicoletti, Effects
of octreotide on glycaemic control, glucose disposal, hepatic Sanaka, M., see Miura, J. 38, 139
glucose production and counterregulatory hormones secre- Sato, T., see Toide, K. 38, 151
tion in type | and type 2 insulin treated diabetic pa- Shahparian, M., see Amini, M. 38, 185
tients 38, 81 Shaw, C.-K., see Chen, H.-D. 38, 199
Shaw, J.E., A.J.M. Boulton, Poor vision as a contributory
Mackay, I.R., see Mohan, V. 38, 101 factor in diabetic neuro-arthropathy 38, 21
Malaisse, W.J., see Fabregat, M.E. 38, 115 Shih-Tzer Tsai, see Chou, P. 38, 61
Man, Z.-W., see Toide, K. 38, 151 Shima, K., see Toide, K. 38, 151
Marco, G., see Franzetti, I. 38, 173 Shirabe, S., see Kanazawa, M. 38, 161
Markopoulos, A.K., M.A. Belazi, D. Drakoulakos, Glutamic Skrha, J., J. Perusi¢ova, P. Pont’uch, A. Ok&a, Glycosamino-
acid decarboxylase autoantibodies in saliva of children with glycan sulodexide decreases albuminuria in diabetic pa-
type | diabetes 38, 169 tients 38, 25
Martinez-Martin, F.J., see de Pablos-Velasco, P.L. 38, 191 Soriguer, F.J., see Pareja, A. 38, 143
Millan, M., see Balsells, M. 38, 123 Szelachowska, M., see Poplawska, A. 38, 109
Miura, J., M. Sanaka, Y. Ikeda, C. Watanabe, T. Nakagami,
N. Iwasaki, Y. Uchigata, C. Takahashi, Y. Omori, Y. Takahashi, C., see Miura, J. 38, 139
Iwamoto, A case of Type-1 diabetes mellitus formerly diag- Takemura, Y., see Inukai, T. 38, 53
nosed as maturity-onset diabetes of the young (MODY) Tanaka, A., see Kanazawa, M. 38, 161
carrying suggestive MODY3 gene 38, 139 Tayama, K., see Inukai, T. 38, 53
Mohan, V., R. Vijayaprabha, M. Rema, G. Premalatha, S. Tinahones, F.J., see Pareja, A. 38, 143
Poongothai, R. Deepa, E. Bhatia, I.R. Mackay, P. Zimmet, Toide, K., Z.-W. Man, Y. Asahi, T. Sato, N. Nakayama, Y.
Clinical profile of lean NIDDM in South India 38, 101 Noma, Y. Oka, K. Shima, Glucose transporter levels in a
Monzon, A., see Pareja, A. 38, 143 male spontaneous non-insulin-dependent diabetes mellitus
Author index
rat of the Otsuka Long-Evans Tokushima Fatty strain 38, Vercruysse, L., see Aerts, L. 38, 9
151 Viadé, J., see Balsells, M. 38, 123
Topolska, J., see Poplawska, A. 38, 109 Vijayaprabha, R., see Mohan, V. 38, 101
Tseng, W.-P., see Chen, H.-D. 38, 199
Uchigata, Y., see Miura, J. 38, 139 Waldbillig, R.J., see Bitar, M.S. 38, 73
Watanabe, C., see Miura, J. 38, 139
Van Assche, F.A., see Aerts, L. 38, 9
Wysocka-Solowie, B., see Poplawska, A. 38, 109
van Houtum, W.H., L.A. Lavery, Methodological issues affect
variability in reported incidence of lower extremity amputa-
tions due to diabetes 38, 177 Zimmet, P., see Mohan, V. 38, 101

DIABETES RESBARCH
AND
CLINICAL PRACTICE
Diabetes Research and Clinical Practice 38 (1997) 211—214
Subject index
Volume 38 (1997)
Acarbose; Diabetes mellitus; Secondary sulfonylurea failure; C-peptide; Lean NIDDM; Non-obese; NIDDM; Complica-
Pharmacotherapy 38, 33 tions; Retinopathy; Nephropathy; Neuropathy; Gad-antibod-
ies; Islet cell antibodies; South India 38, 101
Adipose tissue; Otsuka Long-Evans Tokushima Fatty; Glu-
cose transporter; Insulin resistance; Skeletal muscle 38, 151 Diabetes; Diabetic neuropathy; Diabetic foot; Charcot
foot 38, 21
Albuminuria; Osteocalcin; Vitamin D; Intact PTH; Retinopa-
thy 38, 53 Diabetes mellitus; Acarbose; Secondary sulfonylurea failure;
Pharmacotherapy 38, 33
Albuminuria; Sulodexide; Diabetes mellitus 38, 25
Diabetes mellitus; Albuminuria; Sulodexide 38, 25
Alcohol; Troglitazone; In vitro; Pharmacokinetics; Pharmaco-
dynamic 38, 41 Diabetes mellitus; Foot; Amputation; Incidence; Statistics;
Methodology 38, 177
Amputation; Diabetes mellitus; Foot; Incidence; Statistics;
Methodology 38, 177 Diabetes mellitus; IGF-I; Superior cervical ganglia; IGF-I re-
ceptor 38, 73
Anti-GAD antibody; Type-1 diabetes; MODY 38, 139
Diabetes; Prevalence; Community-based survey 38, 61
Autoantibodies; Mitochondrial glycerophosphate dehydroge-
nase; IDDM __ 38, 115 Diabetic foot; Diabetes; Diabetic neuropathy; Charcot
foot 38, 21
Body mass index; Lipid profile; Systolic blood pressure 38,
185 Diabetic foot ulcers; Osteomyelitis; Bone and leukocyte scan-
ning; Peripheral vascular disease 38, 123
Bone and leukocyte scanning; Diabetic foot ulcers; Osteomyeli-
tis; Peripheral vascular disease 38, 123 Diabetic nephropathy; Glycosaminoglycans; Urinary albumin
excretion rate; Sulodexide 38, 109
Charcot foot; Diabetes; Diabetic neuropathy; Diabetic
foot 38, 21 Diabetic neuropathy; Diabetes; Diabetic foot; Charcot
foot 38, 21
Community-based survey; Diabetes; Prevalence 38, 61
Dislipemia; Type 1 diabetes; Nephropathy; Hypertension;
Complications; Lean NIDDM; Non-obese; NIDDM; Prevalence 38, 191
Retinopathy; Nephropathy; Neuropathy; C-peptide; Gad-anti-
bodies; Islet cell antibodies; South India 38, 101 Education; Evaluation; Newcastle 38, 91
Counterregulatory hormones; Hepatic glucose production; Oc- Enalapril; Metabolic acidosis; Metformin; Hyperkaliemia; Non
treotide; Type 1 diabetes; Type 2 diabetes 38, 81 insulin-dependent diabetes mellitus 38, 173
0168-8227/97/$17.00 © 1997 Elsevier Science Ireland Ltd. All rights reserved.
PIT $0168-8227(97)00118-6
212 Subject index
Endocrine pancreas; Islets of Langerhans; Morphometry; Glu- IGF-I receptor; IGF-I; Diabetes mellitus; Superior cervical
cose tolerance; Gestational diabetes; Insulin; Glucagon; So- ganglia 38, 73
matostatin; Pancreatic polypeptide 38, 9
Impaired glucose tolerance; Type 2 diabetes; Prevalence; Ethnic
Ethnic groups; Type 2 diabetes; Impaired glucose tolerance; groups 38, 199
Prevalence 38, 199
Incidence; Diabetes mellitus; Foot; Amputation; Statistics;
Evaluation; Education; Newcastle 38, 91 Methodology 38, 177
Fatty acids; Insulin secretion; Pancreatic islets 38, 143
Insulin; Endocrine pancreas; Islets of Langerhans; Morphome-
try; Glucose tolerance; Gestational diabetes; Glucagon; So-
Foot; Diabetes mellitus; Amputation; Incidence; Statistics;
matostatin; Pancreatic polypeptide 38, 9
Methodology 38, 177
Insulin resistance; Otsuka Long-Evans Tokushima Fatty; Glu-
Gad-antibodies; Lean NIDDM; Non-obese; NIDDM; Compli-
cose transporter; Adipose tissue; Skeletal muscle 38, 151
cations; Retinopathy; Nephropathy; Neuropathy; C-peptide;
Islet cell antibodies; South India 38, 101
Insulin secretion; Fatty acids; Pancreatic islets 38, 143
Gastric acid; Nitric oxide; Rats 38, |
Insulin secretion; OLETF rat; Perfusion; Glucagon secre-
tion 38, 161
Gestational diabetes; Endocrine pancreas; Islets of Langerhans;
Morphometry; Glucose tolerance; Insulin; Glucagon; Somato-
Intact PTH; Osteocalcin; Vitamin D; Albuminuria; Retinopa-
statin; Pancreatic polypeptide 38, 9
thy 38, 53
Glucagon; Endocrine pancreas; Islets of Langerhans; Mor-
phometry; Glucose tolerance; Gestational diabetes; Insulin; In vitro; Troglitazone; Alcohol; Pharmacokinetics; Pharmaco-
Somatostatin; Pancreatic polypeptide 38, 9 dynamic 38, 41
Glucagon secretion; OLETF rat; Perfusion; Insulin §secre- Islet cell antibodies; Lean NIDDM; Non-obese; NIDDM;
tion 38, 161 Complications; Retinopathy; Nephropathy; Neuropathy; C-
peptide; Gad-antibodies; South India 38, 101
Glucose tolerance; Endocrine pancreas; Islets of Langerhans;
Morphometry; Gestational diabetes; Insulin; Glucagon; So- Islets of Langerhans; Endocrine pancreas; Morphometry; Glu-
matostatin; Pancreatic polypeptide 38, 9 cose tolerance; Gestational diabetes; Insulin; Glucagon; So-
matostatin; Pancreatic polypeptide 38, 9
Glucose transporter; Otsuka Long-Evans Tokushima Fatty;
Insulin resistance; Adipose tissue; Skeletal muscle 38, 151
Lean NIDDM; Non-obese; NIDDM; Complications;
Retinopathy; Nephropathy; Neuropathy; C-peptide; Gad-anti-
Glutamic acid decarboxylase; Type | diabetes; Saliva 38, 169
bodies; Islet cell antibodies; South India 38, 101
Glycosaminoglycans; Diabetic nephropathy; Urinary albumin
Lipid profile; Body mass index; Systolic blood pressure 38,
excretion rate; Sulodexide 38, 109
185
Hepatic glucose production; Counterregulatory hormones; Oc-
Metabolic acidosis; Metformin; Hyperkaliemia; Enalapril; Non
treotide; Type | diabetes; Type 2 diabetes 38, 81
insulin-dependent diabetes mellitus 38, 173
Hyperkaliemia; Metabolic acidosis; Metformin; Enalapril; Non
Metformin; Metabolic acidosis; Hyperkaliemia; Enalapril; Non
insulin-dependent diabetes mellitus 38, 173
insulin-dependent diabetes mellitus 38, 173
Hypertension; Type 1 diabetes; Nephropathy; Dislipemia;
Prevalence 38, 191 Methodology; Diabetes mellitus; Foot; Amputation; Incidence;
Statistics 38, 177
IDDM; Autoantibodies; Mitochondrial glycerophosphate de-
hydrogenase 38, 115 Mitochondrial glycerophosphate dehydrogenase; Autoantibod-
ies; IDDM 38, 115
IGF-I; Diabetes mellitus; Superior cervical ganglia; IGF-I
receptor 38, 73 MODY; Type-! diabetes; Anti-GAD antibody 38, 139
Subject index 213
Morphometry; Endocrine pancreas; Islets of Langerhans; Glu- Peripheral vascular disease; Diabetic foot ulcers; Osteomyelitis;
cose tolerance; Gestational diabetes; Insulin; Glucagon; So- Bone and leukocyte scanning 38, 123
matostatin; Pancreatic polypeptide 38, 9
Pharmacodynamic; Troglitazone; Alcohol; In vitro; Pharma-
cokinetics 38, 41
Nephropathy; Lean NIDDM; Non-obese; NIDDM; Complica-
tions; Retinopathy; Neuropathy; C-peptide; Gad-antibodies;
Islet cell antibodies; South India 38, 101 Pharmacokinetics; Troglitazone; Alcohol; In vitro; Pharmaco-
dynamic 38, 41
Nephropathy; Type 1 diabetes; Hypertension; Dislipemia;
Pharmacotherapy; Diabetes mellitus; Acarbose; Secondary sul-
Prevalence 38, 191
fonylurea failure 38, 33
Nephropathy; Type | diabetes; Risk factors; Spain 38, 129
Prevalence; Diabetes; Community-based survey 38, 61
Neuropathy; Lean NIDDM; Non-obese; NIDDM; Complica-
Prevalence; Type 2 diabetes; Impaired glucose tolerance; Eth-
tions; Retinopathy; Nephropathy; C-peptide; Gad-antibodies;
nic groups 38, 199
Islet cell antibodies; South India 38, 101
Prevalence; Type | diabetes; Nephropathy; Hypertension; Dis-
Newcastle; Evaluation; Education 38, 91
lipemia 38, 191
NIDDM; Lean NIDDM; _ Non-obese; Complications;
Rats; Gastric acid; Nitric oxide 38, |
Retinopathy; Nephropathy; Neuropathy; C-peptide; Gad-anti-
bodies; Islet cell antibodies; South India 38, 101
Retinopathy; Lean NIDDM; Non-obese; NIDDM; Complica-
tions; Nephropathy; Neuropathy; C-peptide; Gad-antibodies;
Nitric oxide; Gastric acid; Rats 38, |
Islet cell antibodies; South India 38, 101
Non insulin-dependent diabetes mellitus; Metabolic acidosis;
Retinopathy; Osteocalcin; Vitamin D; Intact PTH; Albumin-
Metformin; Hyperkaliemia; Enalapril 38, 173
uria 38, 53
Non-obese; Lean NIDDM; NIDDM; _ Complications;
Risk factors; Type | diabetes; Nephropathy; Spain 38, 129
Retinopathy; Nephropathy; Neuropathy; C-peptide; Gad-anti-
bodies; Islet cell antibodies; South India 38, 101
Saliva; Type | diabetes; Glutamic acid decarboxylase 38, 169
Octreotide; Counterregulatory hormones; Hepatic glucose pro-
Secondary sulfonylurea failure; Diabetes mellitus; Acarbose;
duction; Type | diabetes; Type 2 diabetes 38, 81
Pharmacotherapy 38, 33
OLETF rat; Perfusion; Insulin secretion; Glucagon secre-
Skeletal muscle; Otsuka Long-Evans Tokushima Fatty; Glu-
tion 38, 161
cose transporter; Insulin resistance; Adipose tissue 38, 151
Osteocalcin; Vitamin D; Intact PTH; Albuminuria; Retinopa-
Somatostatin; Endocrine pancreas; Islets of Langerhans; Mor-
thy 38, 53 phometry; Glucose tolerance; Gestational diabetes; Insulin;
Glucagon; Pancreatic polypeptide 38, 9
Osteomyelitis; Diabetic foot ulcers; Bone and leukocyte scan-
ning; Peripheral vascular disease 38, 123 South India; Lean NIDDM; Non-obese; NIDDM; Complica-
tions; Retinopathy; Nephropathy; Neuropathy; C-peptide;
Otsuka Long-Evans Tokushima Fatty; Glucose transporter; Gad-antibodies; Islet cell antibodies 38, 101
Insulin resistance; Adipose tissue; Skeletal muscle 38, 151
Spain; Type | diabetes; Nephropathy; Risk factors 38, 129
Pancreatic islets; Fatty acids; Insulin secretion 38, 143
Statistics; Diabetes mellitus; Foot; Amputation; Incidence;
Pancreatic polypeptide; Endocrine pancreas; Islets of Langer- Methodology 38, 177
hans; Morphometry; Glucose tolerance; Gestational diabetes;
Insulin; Glucagon; Somatostatin 38, 9 Sulodexide; Albuminuria; Diabetes mellitus 38, 25
Perfusion; OLETF rat; Insulin secretion; Glucagon secre- Sulodexide; Diabetic nephropathy; Glycosaminoglycans; Uri-
tion 38, 161 nary albumin excretion rate 38, 109
214 Subject index
Superior cervical ganglia; IGF-I; Diabetes mellitus; IGF-I re- Type 2 diabetes; Impaired glucose tolerance; Prevalence; Eth-
ceptor 38, 73 nic groups 38, 199
Systolic blood pressure; Body mass index; Lipid profile 38,
Type-1 diabetes; MODY; Anti-GAD antibody 38, 139
185
Type 1 diabetes; Nephropathy; Hypertension; Dislipemia;
Troglitazone; Alcohol; In vitro; Pharmacokinetics; Pharmaco-
Prevalence 38, 191
dynamic 38, 41
Type 1 diabetes; Nephropathy; Risk factors; Spain 38, 129
Type 2 diabetes; Counterregulatory hormones; Hepatic glucose
production; Octreotide; Type 1 diabetes 38, 81
Urinary albumin excretion rate; Diabetic nephropathy; Gly-
cosaminoglycans; Sulodexide 38, 109
Type 1 diabetes; Counterregulatory hormones; Hepatic glucose
production; Octreotide; Type 2 diabetes 38, 81
Vitamin D; Osteocalcin; Intact PTH; Albuminuria; Retinopa-
thy 38, 53
Type 1 diabetes; Glutamic acid decarboxylase; Saliva 38, 169